The Effects of PXR Activation on Hepatic Fat Content

PXR-aktivaation Vaikutus Maksan Rasvoittumiseen

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02329405

Enrollment

Registered

2014-12-31

Start date

2014-12-31

Completion date

2017-01-31

Last updated

2017-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic Fatty Liver Disease

Brief summary

This study investigates the effects of pregnane X receptor (PXR) activation on hepatic fat content in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to volunteers. Hepatic fat content is measured with magnetic resonance imaging and blood samples are collected at the end of each study arm. The investigators' hypothesis is that rifampicin causes accumulation of fat to the liver.

Interventions

DRUGRifampicin

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers * Body mass index (BMI) 18.5-25 kg/m2

Exclusion criteria

* Systolic blood pressure over 150 mmHg * Any continuous medication (hormonal intrauterine device is permitted) * Any significant medical condition * Insensitivity to rifampicin * Pregnancy and lactation * Previous difficult venipuncture * Alcohol and medicine abuse and drug use * Participation to any other pharmaceutical trial within on month of screening * Claustrophobia * Metal and other implants which are contraindications to MRI

Design outcomes

Primary

Measure	Time frame
Hepatic fat fraction	Day 8

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026